La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Hualan Biological Engineering Crescita futura

Future criteri di controllo 2/6

Hualan Biological Engineering prevede che gli utili e i ricavi cresceranno rispettivamente di 17.5% e 15% all'anno. Si prevede che l'EPS crescerà di 17.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 13.4% in 3 anni.

Informazioni chiave

18.8%

Tasso di crescita degli utili

18.9%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	39.7%
Tasso di crescita dei ricavi	15.5%
Rendimento futuro del capitale proprio	13.3%
Copertura analitica	Good
Ultimo aggiornamento	02 Sep 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Why Investors Shouldn't Be Surprised By Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

Aug 22

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate

Jun 26

Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30

Jun 09

These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely

Jun 07

Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

May 21

Is Hualan Biological Engineering (SZSE:002007) Using Too Much Debt?

Feb 27

Previsioni di crescita degli utili e dei ricavi

SZSE:002007 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	7,985	2,275	2,324	2,125	10
12/31/2025	6,848	1,920	2,476	1,786	12
12/31/2024	5,943	1,638	1,627	1,902	12
6/30/2024	5,409	1,395	256	900	N/A
3/31/2024	5,249	1,392	346	1,027	N/A
12/31/2023	5,342	1,482	592	1,346	N/A
9/30/2023	4,828	1,243	807	1,538	N/A
6/30/2023	3,753	1,020	1,099	1,713	N/A
3/31/2023	4,757	1,194	835	1,268	N/A
1/1/2023	4,517	1,076	563	957	N/A
9/30/2022	4,677	1,139	136	662	N/A
6/30/2022	5,497	1,425	54	704	N/A
3/31/2022	4,453	1,277	474	1,225	N/A
1/1/2022	4,436	1,299	621	1,432	N/A
9/30/2021	5,311	1,709	1,016	1,642	N/A
6/30/2021	4,925	1,559	907	1,594	N/A
3/31/2021	4,969	1,621	764	1,495	N/A
12/31/2020	5,023	1,613	704	1,325	N/A
9/30/2020	4,134	1,284	608	1,166	N/A
6/30/2020	3,684	1,288	902	1,295	N/A
3/31/2020	3,682	1,271	953	1,271	N/A
12/31/2019	3,700	1,283	1,090	1,363	N/A
9/30/2019	3,819	1,344	1,088	1,334	N/A
6/30/2019	3,418	1,194	1,214	1,451	N/A
3/31/2019	3,351	1,192	1,255	1,440	N/A
12/31/2018	3,217	1,140	1,109	1,293	N/A
9/30/2018	2,738	961	746	864	N/A
6/30/2018	2,556	843	467	590	N/A
3/31/2018	2,392	773	N/A	308	N/A
12/31/2017	2,368	821	N/A	177	N/A
9/30/2017	2,195	792	N/A	146	N/A
6/30/2017	2,091	801	N/A	120	N/A
3/31/2017	2,061	843	N/A	203	N/A
12/31/2016	1,935	780	N/A	330	N/A
9/30/2016	1,767	737	N/A	443	N/A
6/30/2016	1,671	690	N/A	585	N/A
3/31/2016	1,585	632	N/A	549	N/A
12/31/2015	1,472	589	N/A	549	N/A
9/30/2015	1,386	575	N/A	501	N/A
6/30/2015	1,372	563	N/A	429	N/A
3/31/2015	1,263	514	N/A	429	N/A
12/31/2014	1,243	538	N/A	497	N/A
9/30/2014	1,237	547	N/A	541	N/A
6/30/2014	1,141	530	N/A	501	N/A
3/31/2014	1,104	519	N/A	503	N/A
12/31/2013	1,118	475	N/A	511	N/A
9/30/2013	1,147	416	N/A	624	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 002007 ( 17.5% all'anno) è superiore al tasso di risparmio ( 2.9% ).

Guadagni vs Mercato: Si prevede che gli utili di 002007 ( 18.8% all'anno) cresceranno più lentamente rispetto al mercato CN ( 22.5% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 002007 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 002007 ( 15% all'anno) crescerà più rapidamente del mercato CN ( 13.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 002007 ( 15% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 002007 sarà basso tra 3 anni ( 13.4 %).

Hualan Biological Engineering Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 7.4% to CN¥22.68

Price target increased to CN¥26.17

Price target decreased to CN¥27.73

Consensus revenue estimates increase by 11%

Price target decreased to CN¥33.57

Price target decreased to CN¥33.57

Recent updates

Price target decreased by 7.4% to CN¥22.68

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Why Investors Shouldn't Be Surprised By Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

Hualan Biological Engineering Inc. to Report First Half, 2024 Results on Aug 30, 2024

Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate

Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30

Dividend of CN¥0.30 announced

Hualan Biological Engineering Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 14 June 2024

These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely

Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Hualan Biological Engineering Inc. to Report Q1, 2024 Results on Apr 26, 2024

Is Hualan Biological Engineering (SZSE:002007) Using Too Much Debt?

Hualan Biological Engineering Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Hualan Biological Engineering Inc. Announces Final Dividend on Share A for 2022, Payable on June 14, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to CN¥26.17

Less than half of directors are independent

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.11 in 2Q 2021)

Investor sentiment improved over the past week

Hualan Biological Engineering Inc. Announces Final Cash Dividend on A Shares for 2021, Payable on 16 June 2022

Price target decreased to CN¥27.73

Less than half of directors are independent

Investor sentiment improved over the past week

Consensus revenue estimates increase by 11%

Price target decreased to CN¥33.57

Price target decreased to CN¥33.57

Hualan Biological Engineering Inc., Annual General Meeting, Apr 28, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Hualan Biological Engineering Inc. Proposes Final Dividend for the Year 2021

Consensus revenue estimates fall by 32%

Price target decreased to CN¥36.80

Third quarter 2021 earnings released: EPS CN¥0.33 (vs CN¥0.25 in 3Q 2020)

Price target decreased to CN¥41.06

Investor sentiment deteriorated over the past week

Price target decreased to CN¥46.66

Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.14 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.89 (vs CN¥0.71 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.88 (vs CN¥0.70 in FY 2019)

Revenue beats expectations, earnings disappoint

New 90-day low: CN¥39.55

Hualan Biological Engineering Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

Investor sentiment improved over the past week

New 90-day high: CN¥53.98

Investor sentiment improved over the past week

New 90-day low: CN¥42.50

New 90-day low: CN¥46.08

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations, earnings disappoint

Market pulls back on stock over the past week

Earnings released

New 90-day high - CN¥59.83

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita